Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF

Inclusion Criteria: * suitable candidate for intra-cardiac mapping for arrhythmias with documented PAF defined by HRS Criteria. * Eighteen to Eighty years of age * Signed informed consent Exclusion Criteria: * Intracardiac thrombus, tumor or other abnormality that precludes catheter introduction and placement * Severe cerebrovascular disease or history of cerebrovascular event within one (1) month * Patients with severely impaired kidney function as measured by a Cockcroft-Gault Glomerular Filtration Rate (GFR) 3 with a GFR \< 29. * Active gastrointestinal bleeding, infection or fever (\> 100.5/38C) * Severe co morbidity or Short life expectancy (\<1 year) due to other illnesses such as cancer, pulmonary, hepatic or renal disease * Structural heart disease of clinical significance including * Symptoms of congestive heart failure including, but not limited to, NYHA Class III or IV CHF and/or documented ejection fraction \< 40% measured by acceptable cardiac testing * Stable/unstable angina or ongoing myocardial ischemia * Myocardial infarction (MI) within three months of enrollment * Aortic or mitral valve disease \> Grade II * Congenital heart disease (not including ASD or PFO without a right to left shunt) where the underlying abnormality increases the risk of an ablative procedure * Enrollment in any other ongoing arrhythmia study protocol * Any ventricular tachyarrhythmia currently being treated where the arrhythmia or the management may interfere with this study * Active infection or sepsis * Female patient is pregnant or lactating * Untreatable allergy to contrast media * Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiovascular causes * History of blood clotting (bleeding or thrombotic) abnormalities * Known sensitivities to heparin or warfarin * Severe COPD (identified by an FEV1 \<1)